Is DRUG or DYAI more undervalued in 2026?

CirclFi compares Bright Minds Biosciences Inc. (DRUG) and Dyadic International, Inc. (DYAI) using 13 institutional-grade valuation models. DRUG has a Quality of Company score of 4.4/10 while DYAI scores 6.6/10.

Which is a better buy — DRUG or DYAI?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do DRUG and DYAI valuations compare?

DRUG at $89.49 and DYAI at $0.71 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

DRUG vs DYAI Valuation Comparison 2026 — Intrinsic Value Analysis

DRUG

Biotechnology

Bright Minds Biosciences Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$89.49

Last close

Models

8/13

Active

DYAI

Biotechnology

Dyadic International, Inc.

Quality

6.6

out of 10

Value Trap

SAFE

Price

$0.71

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	DRUG Fair Value	DRUG Upside	DYAI Fair Value	DYAI Upside
Bayesian DCF	Intrinsic	$24.06	-73.1%	$0.24	-66.5%
Earnings Power Value	Intrinsic	—	—	$0.21	-74.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$85.26	-4.7%	$0.85	+19.8%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for DRUG vs DYAI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DRUG vs DYAI — Which Stock Is More Undervalued?

DYAI scores higher with a 6.6/10 quality rating vs DRUG's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Bright Minds Biosciences Inc. (DRUG) and Dyadic International, Inc. (DYAI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DRUG currently trades at $89.49 with a QOC of 4.4/10, while DYAI trades at $0.71 with a QOC of 6.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).